Search for content, post, videos

Merck’s molnupiravir reduced the risk of hospitalization or death by 50%

Robert Davis
Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics have announced that molnupiravir, an investigational oral antiviral medicine, significantly reduced the risk of hospitalization or death at a planned interim analysis of the Phase 3 MOVe-OUT trial in at risk, non
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.